Federated Hermes, Inc. Aligos Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.71 - $1.06 $688 - $1,028	-970 Reduced 59.77%	653 $0
Q1 2023 May 08, 2023	SELL	$0.87 - $2.11 $1,354 - $3,285	-1,557 Reduced 48.96%	1,623 $1,000
Q4 2022 Feb 13, 2023	BUY	$0.89 - $28.0 $1,035 - $32,564	1,163 Added 57.66%	3,180 $3,000
Q3 2022 Nov 14, 2022	BUY	$1.06 - $27.5 $2,138 - $55,467	2,017 New	2,017 $2,000
Q2 2022 Aug 15, 2022	SELL	$1.04 - $2.14 $1.53 Million - $3.16 Million	-1,475,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $14.2 Million - $17.3 Million	975,000 Added 195.0%	1,475,000 $22.9 Million
Q4 2020 Feb 12, 2021	BUY	$13.2 - $32.74 $6.6 Million - $16.4 Million	500,000 New	500,000 $13.8 Million

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.66B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.